Fred Alger Management, LLC Mersana Therapeutics, Inc. Transaction History

Fred Alger Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$5.65 - $7.86 $25,735 - $35,802	4,555 Added 1.22%	378,450 $2.22 Million
Q3 2022 Nov 14, 2022	SELL	$4.63 - $8.0 $350,796 - $606,128	-75,766 Reduced 16.85%	373,895 $2.53 Million
Q2 2022 Aug 15, 2022	BUY	$2.84 - $5.0 $359,524 - $632,965	126,593 Added 39.18%	449,661 $2.08 Million
Q1 2022 May 16, 2022	BUY	$3.74 - $6.63 $353,721 - $627,052	94,578 Added 41.39%	323,068 $1.29 Million
Q4 2021 Feb 14, 2022	BUY	$5.48 - $9.86 $1.25 Million - $2.25 Million	228,490 New	228,490 $1.42 Million

130

104M

58.5K

471K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $56.4M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Fred Alger Management, LLC with notifications on news.